Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)

NCT01966419 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

231

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Episode of Overt Hepatic Encephalopathy
Hepatic Encephalopathy

Interventions

DRUG: ornithine phenylacetate
DRUG: placebo intravenous infusion

Sponsor

Ocera Therapeutics, Inc.